Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This review summarizes an illustrative set of data from our research on the reconstruction of structurally complex protein surfaces, i.e. those that fail to be mimicked properly by linear peptides. In the past 5 years, our newly developed CLIPS™ technology has proven an extremely valuable tool for 1) binding site mapping of therapeutically relevant mAbs, 2) generating hyperimmune sera via immunization with CLIPS peptides, and 3) the generation of monoclonal antibodies (mAbs) via the use of hybridoma technology. We currently have data available for more than 50 therapeutic targets. The examples described in this review illustrate the potential of this powerful new technology. © Timmerman et al.; Licensee Bentham Open.

Original publication




Journal article


Open Vaccine Journal

Publication Date





56 - 67